Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2018

View Archived Issues

First patients enrolled in phase IIa trial of ORY-2001 in Alzheimer's disease

Alkahest initiates two phase II trials of ALK-4290 in age-related macular degeneration

FDA approves Briviact oral formulations for the treatment of pediatric patients

Concentric reports topline phase Ib data for CA-008 in postsurgical pain

FDA grants fast track designation to L1-79 for use in autism spectrum disorder

Search for small-molecule PD-1/PD-L1 inhibitors yields JBI-426

Researchers at Ben-Gurion University develop a novel molecule for the treatment of cancer

New ELMO3 gene mutation tied to keratoconus

Galectin proceeds with plans for phase III program with GR-MD-02 in NASH cirrhosis

Lymph-directed compound ST-182 simultaneously inhibits MAPK, PI3K and mTOR

Soleno Therapeutics initiates phase III study of DCCR in Prader-Willi syndrome

FDA accepts for review BLA for pegfilgrastim biosimilar CHS-1701

Researchers develop PXDN-mutant microphthalmia and dysgenesis murine model

Medisix Therapeutics closes series A financing

Zymeworks and Daiichi Sankyo expand immuno-oncology collaboration

FDA approves subcutaneous Actemra for active polyarticular juvenile idiopathic arthritis

NanoViricides confirms progress in HerpeCide program

Nimbus Lakshmi patents TYK2 inhibitors

Chinese researchers divulge Trk inhibitors

Interpace to launch new thyroid test ThyGeNEXT

Pfenex reports topline results from study of PF-708 in osteoporosis

New KDM1A inhibitors developed by Constellation Pharmaceuticals

Recombinant Dodekin has anticancer activity alone or with checkpoint inhibitors

New TTI-622 biologic from Trillium Therapeutics shows antitumoral activity in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...